STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 8th, 2019 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 3, 2019 (the “Effective Date”) by and between Cidara Therapeutics, Inc., a Delaware corporation having its principal offices at 6310 Nancy Ridge Dr., Suite 101, San Diego, CA 92121, USA (the “Company”), and Mundipharma AG, having its principal offices at St.Alban-Rheinweg 74, Basel 4020, Switzerland (the “Purchaser”). Certain terms used and not otherwise defined in the text of this Agreement are defined in Section 9 of this Agreement.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 8th, 2019 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AND LICENSE AGREEMENT (“Agreement”) is entered into as of September 3, 2019 (the “Effective Date”), by and between MUNDIPHARMA MEDICAL COMPANY, a general exempted partnership established and existing under the laws of Bermuda, and having its principal place of business at Par La Ville Place, 14 Par La Ville Road, Hamilton HM08, Bermuda (“Mundipharma”), and CIDARA THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, USA (“Cidara”).
